Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 12, 2004
Alterations in QT dispersion in medicated schizophrenia patients following electroconvulsive therapyEitan Nahshoni, Nira Manor, Faina Bar, et al.
Military Medicine|March 7, 2019
Equine Assisted Therapy for Patients with Post Traumatic Stress Disorder: A Case Series StudyAssaf Shelef, Dorit Brafman, Thom Rosing, et al.
Brain and Behavior|December 15, 2015
Magnetic resonance brain imaging in patients with visual vertigoLea Pollak, Michael Osherov, Nadav Berkovitz, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 4, 2009
Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind studyAyelet Avital, Ruth Gross-Isseroff, Rafael Stryjer, et al.
Harefuah|January 3, 2018
[NEUROPSYCHIATRIC MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS]Rafael Stryjer, Liron Shriki Tal, Alex Gizunterman, et al.
Clinical Neuropharmacology|July 4, 2012
Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophreniaRafael Stryjer, Dana Ophir, Faina Bar, et al.
Clinical Neuropharmacology|September 15, 2010
Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover studyRafael Stryjer, Silvio Rosenzcwaig, Faina Bar, et al.
Clinical Neuropharmacology|June 5, 2003
Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodoneRafael Stryjer, Rael D Strous, Faina Bar, et al.
Frontiers in Psychiatry|March 15, 2024
Short-term chloral hydrate as an add-on treatment may improve sleep and alleviate agitation in inpatients with treatment resistant schizophrenia: a retrospective case series studyAssaf Shelef, Habashi Alaa, Esther Bloemhof-Bris, et al.
International Clinical Psychopharmacology|December 6, 2012
Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective studyRafael Stryjer, Yael Dambinsky, Igor Timinsky, et al.
Pageof 4